TELA Bio Inc.
TELA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TELA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TELA
TELA Bio Inc. is a commercial-stage medical technology company focused on developing and marketing biologic soft-tissue reconstruction products, primarily for hernia repair and abdominal wall reconstruction.
Key risk: Continued operating losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for TELA Bio Inc..
TELA Bio Inc. is a commercial-stage medical technology company focused on developing and marketing biologic soft-tissue reconstruction products, primarily for hernia repair and abdominal wall reconstruction.
- TELA Bio is a commercial-stage company with a focus on biologic soft-tissue reconstruction products [sec_mda · as of 2026-03-25].
- As of June 30, 2026, the company reported cash and equivalents of $30.6 million, total revenue of $19.3 million, and a net loss of $11.3 million [sec].
- The company has an accumulated deficit of $379.9 million as of June 30, 2025 [sec_mda · as of 2025-08-11].
- In March 2024, TELA Bio sold its distribution rights to MiMedx Group, Inc. for an initial $5.0 million payment and future revenue-share payments [sec_mda · as of 2025-11-14].
- TELA Bio completed an underwritten public offering in October 2024, raising proceeds through the sale of common stock and pre-funded warrants [sec_mda · as of 2025-08-11].
What works
- The company has a commercial-stage product portfolio and is generating revenue, with $19.3 million in total revenue for the six months ended June 30, 2026 [sec].
- TELA Bio has a cash position of $30.6 million as of June 30, 2026, which provides a runway for ongoing operations and investment [sec].
- The company has reduced research and development expenses, which decreased by $0.8 million in 2024 compared to 2023, indicating cost management [sec_mda · as of 2025-03-21].
What to weigh
- TELA Bio has incurred operating losses since inception and expects losses to continue in the near term as it invests in sales and marketing [sec_mda · as of 2025-11-14].
- The company has a significant accumulated deficit of $379.9 million as of June 30, 2025 [sec_mda · as of 2025-08-11].
- Total debt stands at $56.1 million as of June 30, 2026, which is a substantial liability relative to equity of $9.2 million [sec].
- The company's revenue is still relatively low compared to its operating expenses, resulting in a net loss of $11.3 million for the first half of 2026 [sec].
From the filings
Quoted directly from source documents.
TELA Bio is a commercial-stage company.
“We are a commercial-stage me”
SEC MD&A · March 25, 2026
The company has an accumulated deficit of $379.9 million.
“of $379.9 million. As of December 31, 2024, we had cash and cash equivalents of $52.7 million, working capital of $62.5 million and an accumulated deficit of $358.7 million.”
SEC MD&A · August 11, 2025
TELA Bio sold its distribution rights to MiMedx Group, Inc.
“In March 2024, we sold our distribution rights to MiMedx Group, Inc. in exchange for an initial $5.0 million payment and additional future revenue-share payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on net sales of NIVIS (now marketed as HELIOGEN) over the subsequent two years.”
SEC MD&A · November 14, 2025
The company completed an underwritten public offering in October 2024.
“On October 24, 2024, we completed an underwritten public offering of 14,670,000 shares of our common stock, including the exercise in full of the underwriters' overallotment option to purchase additional shares of common stock, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so chose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant”
SEC MD&A · August 11, 2025
Risks & what to watch (4)›
Key risks
- Continued operating losses — The company has incurred operating losses since inception and expects losses to continue in the near term [sec_mda · as of 2025-11-14].
- High accumulated deficit — Accumulated deficit of $379.9 million as of June 30, 2025, indicating significant historical losses [sec_mda · as of 2025-08-11].
- Substantial debt burden — Total debt of $56.1 million as of June 30, 2026, which is high relative to equity of $9.2 million [sec].
- Dependence on revenue growth — Revenue of $19.3 million is insufficient to cover operating expenses, leading to net losses [sec].
What to watch
- Revenue growth trajectory and ability to achieve profitability [sec].
- Cash burn rate and potential need for additional financing [sec_mda · as of 2025-11-14].
- Progress in sales and marketing investments to drive product adoption [sec_mda · as of 2025-11-14].
- Any updates on the revenue-share payments from the MiMedx agreement [sec_mda · as of 2025-11-14].
Sources: SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run TELA Bio Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TELA Bio Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
12.1 months
OCF -$9M · Net income -$11M
Lead: Approved
2 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$11.8M
| Holder | Shares | Value |
|---|---|---|
| essex woodlands management, inc. | 7,714,709 | $4.8M |
| vanguard capital management llc | 3,081,248 | $1.9M |
| silverarc capital management, llc | 2,259,312 | $1.4M |
| dafna capital management llc | 1,441,029 | $893K |
| perkins capital management inc | 1,418,328 | $879K |
| citigroup inc | 750,000 | $465K |
| blackrock, inc. | 465,814 | $289K |
| geode capital management, llc | 455,059 | $282K |
| wealthtrust axiom llc | 376,938 | $234K |
| vanguard fiduciary trust co | 211,662 | $131K |
Showing top 10 of 32 institutional holders of TELA Bio Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 2.5%
- Days to cover
- 4.1
- Shares short
- 765,765
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TELA short interestGovernance
Frequently asked questions
What is the AI investment thesis for TELA Bio Inc.?
TELA Bio Inc. is a commercial-stage medical technology company focused on developing and marketing biologic soft-tissue reconstruction products, primarily for hernia repair and abdominal wall reconstruction.
What is TELA Bio Inc.'s lead drug candidate?
TELA Bio Inc.'s most advanced tracked candidate is ovitex (Approved) for Hernia repair and abdominal wall reconstruction.
Who is the CEO of TELA Bio Inc.?
Ms. Heather C. Getz C.P.A., M.B.A. is the chief executive officer of TELA Bio Inc. (TELA).
Where is TELA Bio Inc. headquartered?
TELA Bio Inc. (TELA) is headquartered in Malvern, PA, United States.
What therapeutic areas does TELA Bio Inc. focus on?
TELA Bio Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.